ZOETERMEER, NETHERLANDS, 23 August – Toshiba Medical Systems Europe presents "Low-dose Myocardial Perfusion Imaging" and an update on the CORE320 Multicenter Trial at the European Society of Cardiology Congress in Stockholm, Sweden, 28 August 2010, 12:00pm - 13:30 (Copenhagen room/Zone A/Session 263).
Announced as a "works in progress" at the beginning of this year, this new cardiac application is now available to the European market. It is now possible to perform a comprehensive cardiac functional and morphological analysis in just one, low-dose examination using Toshiba's Aquilion ONE. This technology can reduce the need to perform multiple examinations using different modalities, a true economical advantage and valuable contribution in cardiac healthcare.
CT cardiac imaging, so far, is hampered from quantifying cardiac tissue functionality caused by obstructed coronaries and/or infarcts. In order to visualize the entire heart, other scanners need to move the patient causing undesired, time-delayed contrast distribution over the heart. The unique 16cm z-axis coverage of the Aquilion ONE, allows scanning of the heart at a single moment in time resulting in temporal homogeneous contrast distribution.
Myocardial perfusion is interpreted by comparing rest and stress data. The rest scan is usually performed using a low dose, prospective CT angiography protocol. Pending body mass index and heart-rate, sub-mSv protocols may be applied. After administration of a pharmacological stress agent, a low dose stress scan is performed.
A "low-dose myocardial perfusion" lecture will be given by Prof. D. Newby (Edinburgh, Scotland UK) during the Toshiba Lunch Symposium 28 August, 12:00pm - 13:30 (Copenhagen room/Zone A/Session 263).
CORE320 multi-centre trial
As the next phase in validating advanced cardiac computed tomography technology in a clinical setting, Toshiba Medical Systems is supporting CORE320, the worldwide multi-center trial comparing the effectiveness of 320-detector row dynamic volume CT to conventional angiography and SPECT technology. The trial aims to determine whether the combination of CT angiography and CT myocardial perfusion can identify coronary stenoses that are greater than or equal to 50 percent by Quantitative Coronary Analysis (QCA) and correspond to a SPECT perfusion defect.
An update on CORE320 will be given by Dr. K. Kofoed (Copenhagen, Denmark) during the Toshiba Lunch Symposium 28 August, 12:00pm - 13:30 (Copenhagen room/Zone A/Session 263).
Aquilion ONE is a trademark of Toshiba Medical Systems Corporation.
About Toshiba Medical Systems
With headquarters in Zoetermeer, Netherlands, Toshiba Medical Systems Europe BV markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in Europe.
Toshiba Medical Systems Corporation, a group company of Toshiba Corporation, is a global leading provider of innovative diagnostic medical imaging systems and comprehensive medical solutions, such as CT, X-ray, Ultrasound, MRI and information systems.
Toshiba Corporation is a world leader and innovator in pioneering high technology, a diversified manufacturer and marketer of advanced electronic and electrical products spanning information & communications systems; digital consumer products; electronic devices and components; power systems, including nuclear energy; industrial and social infrastructure systems; and home appliances.
Toshiba was founded in 1875 and today operates a global network of more than 740 companies with 199,000 employees worldwide and annual sales surpassing $74 billion
For more information, visit www.toshiba-medical.eu.